328 Stock Overview
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MeiraGTx Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.30 |
| 52 Week High | US$7.40 |
| 52 Week Low | US$3.26 |
| Beta | 1.27 |
| 1 Month Change | -23.89% |
| 3 Month Change | -32.28% |
| 1 Year Change | -7.73% |
| 3 Year Change | -64.46% |
| 5 Year Change | n/a |
| Change since IPO | -72.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 328 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | 0.7% | 2.0% |
| 1Y | -7.7% | -24.4% | 2.0% |
Return vs Industry: 328 exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 328 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 328 volatility | |
|---|---|
| 328 Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 328's share price has been volatile over the past 3 months.
Volatility Over Time: 328's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 422 | Alexandria Forbes | meiragtx.com |
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial.
MeiraGTx Holdings plc Fundamentals Summary
| 328 fundamental statistics | |
|---|---|
| Market cap | €288.55m |
| Earnings (TTM) | -€78.55m |
| Revenue (TTM) | €13.10m |
22.0x
P/S Ratio-3.7x
P/E RatioIs 328 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 328 income statement (TTM) | |
|---|---|
| Revenue | US$14.02m |
| Cost of Revenue | US$0 |
| Gross Profit | US$14.02m |
| Other Expenses | US$98.04m |
| Earnings | -US$84.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | -599.46% |
| Debt/Equity Ratio | 52.2% |
How did 328 perform over the long term?
See historical performance and comparison